148 related articles for article (PubMed ID: 36435358)
1. Healthcare Costs for Medicare Patients With Hepatocellular Carcinoma in the United States.
Karim MA; Ramezani M; Leroux T; Kum HC; Singal AG
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2327-2337.e9. PubMed ID: 36435358
[TBL] [Abstract][Full Text] [Related]
2. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States.
Kaplan DE; Chapko MK; Mehta R; Dai F; Skanderson M; Aytaman A; Baytarian M; D'Addeo K; Fox R; Hunt K; Pocha C; Valderrama A; Taddei TH;
Clin Gastroenterol Hepatol; 2018 Jan; 16(1):106-114.e5. PubMed ID: 28756056
[TBL] [Abstract][Full Text] [Related]
3. Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma.
Golabi P; Jeffers T; Younoszai Z; Otgonsuren M; Sayiner M; Mishra A; Venkatesan C; Younossi ZM
Ann Hepatol; 2017; 16(4):555-564. PubMed ID: 28611258
[TBL] [Abstract][Full Text] [Related]
4. The burden of illness associated with hepatocellular carcinoma in the United States.
Lang K; Danchenko N; Gondek K; Shah S; Thompson D
J Hepatol; 2009 Jan; 50(1):89-99. PubMed ID: 18977551
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Sanoff HK; Chang Y; Lund JL; O'Neil BH; Dusetzina SB
Oncologist; 2016 Sep; 21(9):1113-20. PubMed ID: 27185615
[TBL] [Abstract][Full Text] [Related]
6. Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States.
Karim MA; Singal AG; Kum HC; Lee YT; Park S; Rich NE; Noureddin M; Yang JD
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):670-680.e18. PubMed ID: 35307595
[TBL] [Abstract][Full Text] [Related]
7. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study.
El-Serag HB; Siegel AB; Davila JA; Shaib YH; Cayton-Woody M; McBride R; McGlynn KA
J Hepatol; 2006 Jan; 44(1):158-66. PubMed ID: 16290309
[TBL] [Abstract][Full Text] [Related]
8. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
Younossi ZM; Otgonsuren M; Henry L; Venkatesan C; Mishra A; Erario M; Hunt S
Hepatology; 2015 Dec; 62(6):1723-30. PubMed ID: 26274335
[TBL] [Abstract][Full Text] [Related]
9. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States.
Davila JA; Duan Z; McGlynn KA; El-Serag HB
J Clin Gastroenterol; 2012 Jan; 46(1):71-7. PubMed ID: 22157221
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries.
Sanoff HK; Chang Y; Stavas JM; Stürmer T; Lund J
J Natl Compr Canc Netw; 2015 Sep; 13(9):1102-10. PubMed ID: 26358794
[TBL] [Abstract][Full Text] [Related]
11. Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study.
Lal LS; Aly A; Le LB; Peckous S; Seal B; Teitelbaum A
Cancer Rep (Hoboken); 2022 May; 5(5):e1504. PubMed ID: 34494389
[TBL] [Abstract][Full Text] [Related]
12. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
[TBL] [Abstract][Full Text] [Related]
13. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
[TBL] [Abstract][Full Text] [Related]
14. Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan.
Hsu CS; Lang HC; Huang KY; Chao YC; Chen CL
Hepatol Int; 2018 Nov; 12(6):531-543. PubMed ID: 30426396
[TBL] [Abstract][Full Text] [Related]
15. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.
Tapper EB; Catana AM; Sethi N; Mansuri D; Sethi S; Vong A; Afdhal NH
Cancer; 2016 Mar; 122(6):852-8. PubMed ID: 26716758
[TBL] [Abstract][Full Text] [Related]
16. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.
Davila JA; Morgan RO; Richardson PA; Du XL; McGlynn KA; El-Serag HB
Hepatology; 2010 Jul; 52(1):132-41. PubMed ID: 20578139
[TBL] [Abstract][Full Text] [Related]
17. Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis.
Nathan H; Hyder O; Mayo SC; Hirose K; Wolfgang CL; Choti MA; Pawlik TM
Ann Surg; 2013 Dec; 258(6):1022-7. PubMed ID: 23299519
[TBL] [Abstract][Full Text] [Related]
18. Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies.
Mair RD; Valenzuela A; Ha NB; Ayoub WS; Daugherty T; Lutchman GA; Garcia G; Ahmed A; Nguyen MH
Clin Gastroenterol Hepatol; 2012 Dec; 10(12):1412-7. PubMed ID: 22902757
[TBL] [Abstract][Full Text] [Related]
19. Surveillance Patterns for Hepatocellular Carcinoma among Screening-Eligible Patients in the Medicare Population.
Papageorge MV; de Geus SWL; Woods AP; Ng SC; Lee S; McAneny D; Tseng JF; Kenzik KM; Sachs TE
Ann Surg Oncol; 2022 Dec; 29(13):8424-8431. PubMed ID: 36057903
[TBL] [Abstract][Full Text] [Related]
20. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.
Shaya FT; Breunig IM; Seal B; Mullins CD; Chirikov VV; Hanna N
Pharmacoeconomics; 2014 Jan; 32(1):63-74. PubMed ID: 24293197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
